Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
DRUG: Cadonilimab|DRUG: Lenvatinib
Objective Response Rate, ORR is the proportion of patients with best response of complete response (CR) and PR, from the first drug administration up to two years
Progression-free Survival (PFS), Time from the date of first study treatment administration to the date of first documented tumor progression or death due to any cause, whichever occurs first, Time Frame: from the first drug administration up to two years|Disease Control Rate (DCR), Proportion of patients whose best overall response is either CR, PR, or SD, from the first drug administration up to two years|Duration of Response(DOR), Time from first documented response (CR or PR) until documented disease progression or death, whichever occurs first, from the first drug administration up to two years|Overall Survival(OS), Time from the date of first study treatment administration to the date of death due to any cause, from the first drug administration up to two years|Adverse event (AE), Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results, From the subject signs the ICF to 90 days after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma